Updated:
Endoceutics
Quebec City-based single-family office managing capital for biochemist Jean-Yves Sgro, deploying into pharma R&D and women's health therapies.
Endoceutics
Endoceutics operates out of Quebec City, Canada, with its founding year not publicly specified. The entity is closely associated with Jean-Yves Sgro, a biochemist and entrepreneur previously known for founding and leading drug-development ventures. The firm functions as a single-family office focused on life sciences, with an emphasis on therapeutic innovation in endocrinology and women's health. The strategy centers on direct investment into drug discovery and clinical-stage assets, rather than passive fund allocations. Endoceutics has sponsored research into propionate and other hormonal therapies, with a pipeline targeting conditions like endometriosis and menopause. The office's asset-class mix spans early-stage pharma R&D, intellectual property acquisition, and operational control of portfolio companies. Known controlled assets include Endoceutics Inc., a clinical-stage biotech company developing therapies for endocrine disorders (per public record). Geographic footprint is North America, primarily Canada and the United States. The firm's team size and additional offices are not publicly disclosed. No recent operational events within the last 24 months have been confirmed in public sources. The entity appears to maintain a lean structure, with Sgro as the key figure. A structural differentiator is Endoceutics' blurring of the line between family office and operating company: it both manages the family's capital and directly executes R&D programs. This vertical integration is rare among single-family offices, which typically separate investment management from operational control. The office has not publicly discussed succession or governance outside of Sgro's leadership.
General information
Firm type
Single Family Office
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
Canada
City
Quebec City
Corporate office
Quebec City, QC, Canada
Sector focus
Frequently asked questions
Who runs investment decisions at Endoceutics?
Investment decisions are closely tied to Jean-Yves Sgro, the firm's founder and a biochemist with a background in drug development. Sgro previously founded Endoceutics Inc., a clinical-stage biotech company, and the family office appears to be an extension of his operations. The firm has not publicly named a separate CIO or investment committee.
How does Endoceutics source proprietary deal flow?
Endoceutics generates deal flow through its own internal research and development programs rather than external sourcing. The firm's focus on endocrine therapies means it identifies compounds in academic or preclinical stages, then funds their advancement. This integrated model reduces reliance on outside venture pipelines.
Is Endoceutics structured as a single family office or does it operate more like a venture firm?
Endoceutics is organized as a single-family office but operates with a venture model — directly funding and managing drug development. It controls Endoceutics Inc., a biotech firm, which blurs traditional boundaries. The structure allows the family to retain operational control and capture upside from clinical milestones.
Does Endoceutics participate in fund commitments or only direct deals?
The firm appears to focus on direct investments and operational control of its portfolio companies, not third-party fund commitments. It has not been reported as an LP in external venture capital or private equity funds. Its capital is deployed directly into R&D and clinical programs.
What investment stages does Endoceutics typically target?
Endoceutics targets early-stage therapeutic development, from preclinical research through clinical trials. Its known portfolio includes programs in Phase I and II trials for hormonal therapies. The office does not publicly disclose stage-specific allocation targets beyond R&D.
Which sectors does Endoceutics explicitly avoid?
The firm does not invest in sectors outside life sciences, with no public presence in technology, real estate, or financial assets. Its narrow focus on endocrine and women's health suggests it avoids broad-based investment strategies entirely.
Where does the underlying wealth come from?
The wealth is not publicly attributed to a specific fortune. Public records tie the firm to Jean-Yves Sgro, but no inheritance or prior business exit has been disclosed. The office likely manages wealth generated from Sgro's previous entrepreneurial ventures in biotech.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: